Authored by James Sheppard
Atlas ventures appointed Jason Rhodes as a Partner in its life sciences team. Jason arrives at Atlas from Epizyme where he was President and Chief Financial Officer (CFO). At Atlas, Rhodes will head the new investment firm Raze Therapeutics.
The Belgian biotechnology company Galapagos has announced the appointment of its new CFO, Bart Filius. Bart joins Galapagos on December 1st from Sanofi where he was Vice President, CFO for Sanofi Europe.
The venture capital giant New Enterprise Associates (NEA) announced that industry veteran Carol Gallagher would join the firm as a partner. Dr Gallagher is also the Chairman of Atara Biotherapeutics and AnaptysBio. Previous to this Dr Gallagher was President and CEO of Calistoga Pharmaceuticals which was acquired by Gilead in 2011.
The London, UK based biotechnology company Verona Pharmaceuticals announced the appointment of Biresh Roy as the company’s new CFO. Biresh joins Verona from Ebury Capital a company which he founded in 2012.
The USA based biotechnology company Incyte Corp announced that David Gryska will join the company as there new CFO. Mr Gryska succeeds David Hastings who is leaving the company. Mr Gryska was previously Chief Operating Officer at the oncology biotech Myrexis.
Karolinska Development announced that Bruno Lucidi had been appointed permanent CEO following the departure of Torbjorn Bjerke. Bruno joins Karolinska from Idenix where he was CEO. Bruno was also the Chairman of Pharmasset which was purchased by Gilead in 2011.
Global biotech giant Amgen announced that it had appointed Dr. R Sanders Williams to the board of directors. Dr Williams is currently the President of Gladstone Institute, a not for profit biomedical research enterprise.
The rare disease specialist Raptor Pharmaceutical announced two management appointments with Mr David Happel and Dr Kimberley Lee joining the team. Mr Happel joins as Chief Commercial Officer and will oversee Raptors global commercial Operations and Dr Lee joins as Vice President, Corporate Strategy and Communications.
The Massachusetts biotech company Eleven Biotherapeutics announced the appointment of Dr Wendy Dixon to its board of directors. Dr Dixon is the former chief marketing officer and President of global marketing for Bristol Myers Squibb.
Cubist Pharmaceuticals announced that Robert Perez will become the company’s new CEO when Mike Bonney retires on the 31st December. Mr Perez is currently the company’s President and Chief Operating Officer.